| 0.519 0.012 (2.33%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.79 | 1-year : | 1.06 |
| Resists | First : | 0.67 | Second : | 0.91 |
| Pivot price | 0.51  |
|||
| Supports | First : | 0.3 | Second : | 0.24 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.55  |
| MA(100) : | 0.51 |
MA(250) : | 0.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.6 |
D(3) : | 34.8 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 1.5 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ORGS ] has closed below upper band by 43.6%. Bollinger Bands are 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.52 - 0.52 | 0.52 - 0.52 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.51 - 0.52 | 0.52 - 0.52 |
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Mon, 04 Mar 2024
Orgenesis secures $2.3 million in private placement By Investing.com - Investing.com
Mon, 04 Mar 2024
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119% - Simply Wall St
Thu, 15 Feb 2024
Dakota Gold And 2 Other Stocks Under $3 Insiders Are Buying - Markets Insider
Thu, 01 Feb 2024
Orgenesis Inc Strikes Definitive Deal to Acquire Octomera LLC - TipRanks.com - TipRanks
Thu, 25 Jan 2024
Orgenesis Inc. Secures Acquisition of Octomera LLC - TipRanks.com - TipRanks
Wed, 22 Nov 2023
Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 3.006e+007 (%) |
| Held by Institutions | 20.3 (%) |
| Shares Short | 226 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.064e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 213.3 % |
| Return on Equity (ttm) | -61.9 % |
| Qtrly Rev. Growth | 530000 % |
| Gross Profit (p.s.) | -89.82 |
| Sales Per Share | -308.26 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.87 |
| Dividend | 0 |
| Forward Dividend | 299690 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|